Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary T Ferguson

Showing results (21-30 of 103) with videos related to

Pageof 11
Sort By:
Respiratory Medicine|July 11, 2008
Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsGary T Ferguson, Antonio Anzueto, Richard Fei, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|November 11, 2017
In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation SolutionStephen Pham, Gary T Ferguson, Edward Kerwin, et al.
Advances in Therapy|May 29, 2020
Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO<sup>®</sup> and OTEMTO<sup>®</sup> StudiesRoland Buhl, Dave Singh, Alberto de la Hoz, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 18, 2020
Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at BaselineGary T Ferguson, Asif Shaikh, Kay Tetzlaff, et al.
Journal of Asthma and Allergy|November 8, 2019
Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial ResultsGary T Ferguson, Jeremy Cole, Magnus Aurivillius, et al.
Respiratory Medicine|August 26, 2017
Efficacy and safety of glycopyrrolate/eFlow<sup>®</sup> CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trialsEdward Kerwin, James F Donohue, Thomas Goodin, et al.
Pulmonary Pharmacology & Therapeutics|March 24, 2018
Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technologyGary T Ferguson, Colin Reisner, James Pearle, et al.
Therapeutic Advances in Respiratory Disease|February 29, 2020
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trialsSanjay Sethi, James F Donohue, Gary T Ferguson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 3, 2011
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claimsDouglas W Mapel, Anand A Dalal, Christopher M Blanchette, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 3, 2018
Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPDGary T Ferguson, Roberto Rodriguez-Roisin, Colin Reisner, et al.
Pageof 11

Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
Respiratory Medicine|July 11, 2008
Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsGary T Ferguson, Antonio Anzueto, Richard Fei, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|November 11, 2017
In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation SolutionStephen Pham, Gary T Ferguson, Edward Kerwin, et al.
Advances in Therapy|May 29, 2020
Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO<sup>®</sup> and OTEMTO<sup>®</sup> StudiesRoland Buhl, Dave Singh, Alberto de la Hoz, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 18, 2020
Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at BaselineGary T Ferguson, Asif Shaikh, Kay Tetzlaff, et al.
Journal of Asthma and Allergy|November 8, 2019
Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial ResultsGary T Ferguson, Jeremy Cole, Magnus Aurivillius, et al.
Respiratory Medicine|August 26, 2017
Efficacy and safety of glycopyrrolate/eFlow<sup>®</sup> CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trialsEdward Kerwin, James F Donohue, Thomas Goodin, et al.
Pulmonary Pharmacology & Therapeutics|March 24, 2018
Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technologyGary T Ferguson, Colin Reisner, James Pearle, et al.
Therapeutic Advances in Respiratory Disease|February 29, 2020
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trialsSanjay Sethi, James F Donohue, Gary T Ferguson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 3, 2011
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claimsDouglas W Mapel, Anand A Dalal, Christopher M Blanchette, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 3, 2018
Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPDGary T Ferguson, Roberto Rodriguez-Roisin, Colin Reisner, et al.
Pageof 11